161 related articles for article (PubMed ID: 25539793)
1. Cardiovascular risk in Egyptian healthy consumers of different types of combined oral contraceptives pills: A comparative study.
El-Haggar SM; Mostafa TM
Endocrine; 2015 Aug; 49(3):820-7. PubMed ID: 25539793
[TBL] [Abstract][Full Text] [Related]
2. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin, leptin and lipid profiles evaluation in oral contraceptive pill consumers.
Fallah S; Sanjary Pour M; Rabbani Chadegani A; Korani M
Arch Gynecol Obstet; 2012 Jun; 285(6):1747-52. PubMed ID: 22210292
[TBL] [Abstract][Full Text] [Related]
4. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
6. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
[TBL] [Abstract][Full Text] [Related]
7. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
8. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
9. Combined oral contraceptives: venous thrombosis.
de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
[TBL] [Abstract][Full Text] [Related]
10. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
Rechberger T; Tomaszewski J; Pieprzowska-Białek A; Kulik-Rechberger B; Skorupski P
Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792
[TBL] [Abstract][Full Text] [Related]
11. Drospirenone: high risk of venous thrombosis.
Prescrire Int; 2011 Feb; 20(113):43-5. PubMed ID: 21488592
[TBL] [Abstract][Full Text] [Related]
12. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
[TBL] [Abstract][Full Text] [Related]
13. [The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function].
Szlendak-Sauer K; Radowicki S; Skórzewska K
Ginekol Pol; 2009 Feb; 80(2):99-102. PubMed ID: 19338205
[TBL] [Abstract][Full Text] [Related]
14. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
Lepot MR; Gaspard UJ
Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial.
Brill K; Then A; Beisiegel U; Jene A; Wünsch C; Leidenberger F
Contraception; 1996 Nov; 54(5):291-7. PubMed ID: 8934063
[TBL] [Abstract][Full Text] [Related]
17. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
18. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
Dinger J; Möhner S; Heinemann K
Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
